| scholarly article | Q13442814 |
| P2093 | author name string | Cazenave JP | |
| Gachet C | |||
| Ravanat C | |||
| Heitz A | |||
| Rochoux G | |||
| Aleil B | |||
| P2860 | cites work | Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study | Q28165115 |
| Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance | Q28166663 | ||
| Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting | Q28175884 | ||
| Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation | Q28188284 | ||
| Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial | Q28194232 | ||
| Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity | Q28196405 | ||
| Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation | Q28196513 | ||
| Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis | Q28199086 | ||
| Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel | Q28370733 | ||
| A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee | Q29620666 | ||
| Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study | Q33333456 | ||
| Progress in the assessment of platelet function | Q34106873 | ||
| Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction | Q34168972 | ||
| Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for the unidirectional control of platelet function by cyclic AMP | Q40195784 | ||
| The P2Y(12) receptor induces platelet aggregation through weak activation of the alpha(IIb)beta(3) integrin--a phosphoinositide 3-kinase-dependent mechanism | Q43744121 | ||
| A Gi-dependent pathway is required for activation of the small GTPase Rap1B in human platelets | Q43869554 | ||
| Activation of Rap1B by G(i) family members in platelets | Q43968783 | ||
| Individual variations of platelet inhibition after loading doses of clopidogrel | Q44148275 | ||
| Identification of P2Y12-dependent and -independent mechanisms of glycoprotein VI-mediated Rap1 activation in platelets | Q44189548 | ||
| Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. | Q44545487 | ||
| Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function — a flow cytometry study | Q44604925 | ||
| Compliance with aspirin or placebo in the hypertension optimal treatment (HOT) study | Q57987943 | ||
| P433 | issue | 1 | |
| P921 | main subject | patient | Q181600 |
| phosphorylation | Q242736 | ||
| cardiovascular disease | Q389735 | ||
| clopidogrel | Q410237 | ||
| flow cytometry | Q1141429 | ||
| P304 | page(s) | 85-92 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | Journal of Thrombosis and Haemostasis | Q6296004 |
| P1476 | title | Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases | |
| P478 | volume | 3 |
| Q47570792 | A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study |
| Q38672923 | A Safety Evaluation of Cangrelor in Patients Undergoing PCI. |
| Q39017052 | A novel mutation in the P2Y12 receptor and a function-reducing polymorphism in protease-activated receptor 1 in a patient with chronic bleeding |
| Q34761979 | A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI |
| Q40329955 | A point-of-care assay to measure platelet aggregation in patients taking clopidogrel |
| Q39645121 | A potential role for α-actinin in inside-out αIIbβ3 signaling |
| Q38037121 | Advances in the monitoring of anti-P2Y12 therapy. |
| Q42909234 | Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors. |
| Q45164756 | Altered platelet contents in survivors of early ischemic ventricular fibrillation: preliminary findings |
| Q28543952 | Another "string to the bow" of PJ34, a potent poly(ADP-Ribose)polymerase inhibitor: an antiplatelet effect through P2Y12 antagonism? |
| Q38543308 | Antiplatelet drugs: which targets for which treatments? |
| Q37049655 | Antiplatelet therapy for stroke prevention |
| Q46494893 | Antiplatelet therapy in acute coronary syndromes |
| Q28218702 | Antiplatelet therapy in populations at high risk of atherothrombosis |
| Q34771381 | Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance |
| Q38132923 | Assessing post-treatment platelet reactivity: a focus on patient selection and setting. |
| Q28196714 | Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers |
| Q83363907 | Can the PFA-100 be modified to detect P2Y12 inhibition? |
| Q38153779 | Cangrelor: a review on pharmacology and clinical trial development |
| Q37841560 | Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention |
| Q38154064 | Clopidogrel "resistance": pre- vs post-receptor determinants. |
| Q37786639 | Clopidogrel in acute coronary syndrome: implications of recent study findings |
| Q42003164 | Clopidogrel resistance "Live" - the risk of stent thrombosis should be evaluated before procedures |
| Q40347840 | Clopidogrel resistance: fact and fiction |
| Q28218055 | Clopidogrel resistance: myth or reality? |
| Q38274517 | Clopidogrel resistance: the way forward |
| Q46253334 | Comparative Long-Term Effect of Three Anti-P2Y12 Drugs after Percutaneous Angioplasty: An Observational Study Based on Electronic Drug Adherence Monitoring. |
| Q42055431 | Comparison of VerifyNow-P2Y12 test and Flow Cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel therapy? |
| Q36976793 | Comparison of a new P2Y12 receptor specific platelet aggregation test with other laboratory methods in stroke patients on clopidogrel monotherapy |
| Q33636020 | Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition |
| Q48324589 | Comparison of cytotoxic and anti-platelet activities of polyphenolic extracts from Arnica montana flowers and Juglans regia husks. |
| Q37629641 | Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. |
| Q37774825 | Considerations in patients receiving oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention |
| Q33760816 | Correlations between High Platelet Reactivity, Extent of Coronary Artery Disease, and Periprocedural Myonecrosis in Patients with Acute Coronary Syndrome |
| Q54236665 | Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome. |
| Q37752222 | Dosing strategies for antiplatelet therapy in percutaneous coronary intervention. |
| Q28198683 | Drug insight: Clopidogrel nonresponsiveness |
| Q34983154 | Drug-drug interaction between clopidogrel and the proton pump inhibitors. |
| Q46638114 | Effect of long-term adherence to clopidogrel on the VASP-PRI after elective coronary stent implantation: a randomized controlled study. |
| Q38694069 | Effects of P2Y12 receptor antagonists beyond platelet inhibition--comparison of ticagrelor with thienopyridines |
| Q46367587 | Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100. |
| Q43744458 | Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation. |
| Q46477005 | Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients. |
| Q47792745 | Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome. |
| Q45872542 | Evaluation of the INNOVANCE PFA P2Y test cartridge: sensitivity to P2Y(12) blockade and influence of anticoagulant. |
| Q54546944 | Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance. |
| Q28200552 | Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance' |
| Q42245649 | Expression of miRNA-26a in platelets is associated with clopidogrel resistance following coronary stenting |
| Q30450312 | High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study |
| Q53837582 | How to test the effect of aspirin and clopidogrel in patients on dual antiplatelet therapy? |
| Q37203987 | Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome |
| Q47654408 | Impact of acute exacerbations on platelet reactivity in chronic obstructive pulmonary disease patients |
| Q28542407 | Impact of aspirin and clopidogrel interruption on platelet function in patients undergoing major vascular surgery |
| Q36045746 | Impaired P2Y12 inhibition by clopidogrel in kidney transplant recipients: results from a cohort study |
| Q38154612 | Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account |
| Q37378896 | Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Wo |
| Q24629255 | International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy |
| Q37509443 | Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor |
| Q51572866 | Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance. |
| Q46789035 | Monitoring of clopidogrel-related platelet inhibition: correlation of nonresponse with clinical outcome in supra-aortic stenting |
| Q36359617 | New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors |
| Q37799114 | Novel antiplatelet therapy |
| Q38780997 | Novel strategies for assessing platelet reactivity |
| Q37562606 | P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. |
| Q26861200 | P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cells |
| Q89860277 | P2Y12 Inhibition beyond Thrombosis: Effects on Inflammation |
| Q36536498 | P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease |
| Q38051192 | P2Y12 receptor: platelet thrombus formation and medical interventions. |
| Q37642822 | Personalized antiplatelet therapy for coronary artery disease patients: is this the future? |
| Q38154211 | Pharmacology of antiplatelet agents |
| Q58071120 | Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study |
| Q91055048 | Phosphoflow cytometry and barcoding in blood platelets: Technical and analytical considerations |
| Q28200541 | Plasma levels of the growth arrest-specific gene 6 product (Gas6) and antiplatelet drug responsiveness in healthy subjects |
| Q41574497 | Platelet Aggregometry Testing: Molecular Mechanisms, Techniques and Clinical Implications. |
| Q92637510 | Platelet Function Test Use for Patients with Coronary Artery Disease in the Early 2020s |
| Q34325757 | Platelet aggregation and clot formation in comatose survivors of cardiac arrest treated with induced hypothermia and dual platelet inhibition with aspirin and ticagrelor; a prospective observational study |
| Q38068348 | Platelet function monitoring and clopidogrel |
| Q38094681 | Platelet function testing and tailored antiplatelet therapy |
| Q53281424 | Platelet function testing in hirudin and BAPA anticoagulated blood. |
| Q38089082 | Platelet function tests for the monitoring of P2Y12 inhibitors |
| Q35121464 | Platelet function tests: a comparative review |
| Q44426942 | Poor agreement between light transmission aggregometry, Verify Now P2Y₁₂ and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: a potential explanation of negative results of recent randomized trials. |
| Q37809122 | Poor responsiveness to antiplatelet drugs in acute coronary syndromes: clinical relevance and management. |
| Q41742863 | Post receptor determinants of acute platelet response to clopidogrel in patients with symptomatic myocardial ischemia. |
| Q46761762 | Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation |
| Q39908656 | Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system |
| Q37540088 | Recent developments in clopidogrel pharmacology and their relation to clinical outcomes |
| Q28218401 | Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation |
| Q43405386 | Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay |
| Q28192298 | Resistance to antiplatelet drugs: current status and future research |
| Q37807524 | Resistance to aspirin and clopidogrel therapy. |
| Q60018207 | Résistance au clopidogrel, tests génétiques et tests fonctionnels |
| Q30373414 | State-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus. |
| Q26801874 | The Emerging Role of miR-223 in Platelet Reactivity: Implications in Antiplatelet Therapy |
| Q42929936 | The Influence of Proton Pump Inhibitors on the Antiplatelet Potency of Clopidogrel Evaluated by 5 Different Platelet Function Tests |
| Q38306767 | The P2Y(12) receptor as a target of antithrombotic drugs |
| Q46820390 | The Retention Index Test Homburg (RTH-II): Response to clopidogrel and comparison with aggregometry and CD62P-expression |
| Q42159559 | The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel |
| Q53298721 | The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y12receptor inhibition |
| Q89746429 | Ticagrelor and preconditioning in patients with stable coronary artery disease (TAPER-S): a randomized pilot clinical trial |
| Q41817424 | Towards personalized medicine based on platelet function testing for stent thrombosis patients |
| Q50940673 | Validation of a New ELISA-Based Vasodilator-Associated Stimulated Phosphoprotein Phosphorylation Assay to Assess Platelet Reactivity Index in a Chinese Population. |
| Q30498026 | Variable effect of P2Y12 inhibition on platelet thrombus volume in flowing blood |
| Q41620783 | Variations in Intraplatelet Phospho-VASP Expression Due to Pre-analytical Sample Preparations, Illustration of a Quality Control Issue in Platelet Pharmacology |
| Q53554561 | Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. |
| Q43165529 | VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation |
Search more.